Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab
- 30 September 2006
- journal article
- case report
- Published by Elsevier in The Lancet Oncology
- Vol. 7 (9) , 778-780
- https://doi.org/10.1016/s1470-2045(06)70864-6
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Application of intrathecal trastuzumab (Herceptin™) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancerOncology Reports, 2006
- Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapyAnnals of Oncology, 2005
- Durable Remission of Leptomeningeal Metastasis of Breast Cancer with Letrozole: a Case Report and Implications of Biomarkers on Treatment SelectionJapanese Journal of Clinical Oncology, 2003
- HER2 in Brain Metastases: Issues of Concordance, Survival, and TreatmentJournal of Clinical Oncology, 2002
- Use of Intrathecal Trastuzumab in a Patient with Carcinomatous MeningitisClinical Breast Cancer, 2001
- Response of leptomeningeal metastases from breast cancer to hormonal therapyNeurology, 2000
- Trastuzumab in CSFJournal of Clinical Oncology, 2000
- High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?Journal of Clinical Oncology, 1998
- Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacyJournal of Neurosurgery, 1995